Form 4: Schrodinger Director van Kralingen Receives Stock Options and Restricted Stock Units

Director Bridget A van Kralingen reports the acquisition of stock options and restricted stock units in Schrodinger, Inc.

Summary

• Bridget A van Kralingen, a director of Schrodinger, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• On March 7, 2025, van Kralingen was granted 10,000 restricted stock units (RSUs) and an option to purchase 17,050 shares of common stock at an exercise price of $21.02.
• The RSUs and stock options vest in three equal annual installments starting on March 7, 2026, subject to continued service.
• Settlement of the RSUs will be deferred until the earlier of separation from service or a change in control event.
• Van Kralingen also has a Limited Power of Attorney designating Yvonne Tran, Donald Shum, Elizabeth Schauber and Jenny Herman to act on her behalf for Section 16 reporting obligations.

Sentiment

Score: 7

Explanation: The document reflects a standard equity grant to a director, which is generally viewed positively as it aligns interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service with the company.

Future Outlook

The RSUs and stock options will vest over the next three years, incentivizing continued service.

Industry Context

Grants of stock options and restricted stock units are common practice for compensating and incentivizing directors in publicly traded companies, particularly in the technology and biotechnology sectors.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, especially in the tech and biotech industries.
• Companies like Moderna, BioNTech, and similar firms in the pharmaceutical and technology sectors often use equity-based compensation to align director interests with shareholder value.
• The vesting schedule of three years is also a common industry practice to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term success.
• The vesting schedule incentivizes the director to remain with the company, providing stability.

Key Dates